Neurodegeneration with brain iron accumulation
Neurodegeneration with brain iron accumulation | |
---|---|
Other names | NBIA |
Specialty | Neurology |
Neurodegeneration with brain iron accumulation is a heterogenous group of inherited
Iron accumulation can occur anywhere in the brain, with accumulation typically occurring in globus pallidus, substantia nigra, pars reticula, striatum and cerebellar dentate nuclei.[4] Symptoms can include various movement disorders, neuropsychiatric issues, seizures, visual disturbances, and cognitive decline, usually in different combinations.[4] Ten to fifteen genetic NBIA disorders involving various cell processes have been identified: iron metabolism, coenzyme A biosynthesis, phospholipid metabolism, ceramide metabolism, lysosomal disorders, as well as mutations in genes with unknown functions.[5][4] Onset can occur at different ages, from early childhood to late adulthood.[4]
As of 2021[update] there were no curative treatments for any of the NBIA disorders, though several medications have been subject to clinical trial including the iron chelator deferiprone.[5]
Variants
NBIA variant | Gene | Inheritance |
---|---|---|
Pantothenate kinase-associated neurodegeneration (PKAN)[8] | PANK2 | autosomal recessive |
PLA2G6-associated neurodegeneration (PLAN)[9] | PLA2G6 | autosomal recessive |
Mitochondrial membrane protein-associated neurodegeneration (MPAN)[10] | C19orf12 | autosomal recessive or dominant |
Beta-propeller protein-associated neurodegeneration (BPAN)[11] |
WDR45 | X-linked dominant (mostly de novo mutations) |
Fatty acid hydroxylase-associated neurodegeneration (FAHN)[12] | FA2H | autosomal recessive |
Kufor–Rakeb syndrome | ATP13A2 | autosomal recessive |
Neuroferritinopathy | FTL | autosomal dominant |
Aceruloplasminemia | CP | autosomal recessive |
Woodhouse–Sakati syndrome | DCAF17 | autosomal recessive |
COASY protein-associated neurodegeneration (CoPAN) | COASY | autosomal recessive |
NBIA7[13] | REPS1 | autosomal recessive |
NBIA8[13] | CRAT | autosomal recessive |
Diagnosis
Treatments
Effective disease-modifying treatments have not yet been found for any of the NBIA disorders.[5] Treatment is supportive and focused on improving symptoms: Dystonia is a common debilitating symptom and can be managed with oral medications, and sometimes with deep-brain electrical stimulation, therapy support for walking, eating, and manual tasks is essential. Later, in many of the diseases, slowing and stopping of movement (known as parkinsonism) can become common. Removal of iron, using medications known as iron chelators, has been tested in clinical trial but was not definitively shown to be effective.[17]
References
- )
- PMID 26707700.
- PMID 18981035.
- ^ PMID 22691760.
- ^ PMID 34909266.
- PMID 23447832.
- PMID 25614780.
- PMID 20301663.
- PMID 20301718.
- PMID 24575447.
- PMID 28211668.
- PMID 21735565.
- ^ PMID 29395073.
- ^ Brüggemann N. et al.: Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol. 2010 Nov;67(11):1357-63. doi: 10.1001/archneurol.2010.281.
- ^ PMID 16775270.
- PMID 22704258.
- S2CID 186245765.
External links
- Neurodegeneration with Brain Iron Accumulation information page from the National Institute of Neurological Disorders and Stroke